2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 108

Does Receiving Physical Therapy for Knee Osteoarthritis Impact Downstream Healthcare Utilization?

Health Services Research - ARHP Poster

9:00AM-11:00AM: Abstract Number: 562

Does Surgical Intervention to the Upper Extremity Make the Patients with Rheumatoid Arthritis Happy?

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 729

Does the Presence of Multiple Spondyloarthritis-Features in Patients with Chronic Back Pain Always Lead to Diagnosis of Axial Spondyloarthritis?

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster I: Axial and Peripheral Spondyloarthritis – Clinical Aspects, Imaging and Treatment

9:00AM-11:00AM: Abstract Number: 808

Down-Regulation of microRNA-126 in Scleroderma Microvascular Endothelial Cells (MVECs) Is Associated with Impaired Responses to Vascular Endothelial Growth Factor (VEGF) and Defective Angiogenesis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster I

9:00AM-11:00AM: Abstract Number: 784

Drivers of the SLE Responder Index (SRI) Endpoint in Clinical Trials of SLE

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 11

Drug Prescribing Trends in Adults with Rheumatoid Arthritis: A Population-Based Comparative Study from 2005-2014

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 327

Drug Retention Rate of Oral Bisphosphonate in Patients with Rheumatoid Arthritis

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 481

Dual Effect of 3-Bromopyruvate on Both Th17 and Treg Cell Differentiation and Dendritic Cell Activation Ameliorates Autoimmune Arthritis in Mice

Rheumatoid Arthritis – Animal Models - Poster I

9:00AM-11:00AM: Abstract Number: 36

Dysautonomia and Osteoporosis in 2300 Ehlers-Danlos Hypermobile Patients, As Defined By the Brighton Criteria

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster I: Basic Science Focus

9:00AM-11:00AM: Abstract Number: 73

Dysregulation of Hypomethylated Age-Related CpG Sites Characterize T-Cells and Monocytes from Treatment Naive Rheumatoid Arthritis Subjects

Genetics, Genomics and Proteomics - Poster I

9:00AM-11:00AM: Abstract Number: 489

Early Detection of Inflammatory Arthritis: The Role of Musculoskeletal Symptoms, Infections and Rheumatoid Arthritis-Related Comorbidities in Primary Care

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 115

Early Inflammatory Arthritis Presentation, Management and Outcomes in Canadian Aboriginal Patients

Healthcare Disparities in Rheumatology - Poster I

9:00AM-11:00AM: Abstract Number: 325

Ebselen Is a Potential Anti-Osteoporosis Agent By Suppressing RANK Ligand-Induced Osteoclast Differentiation in Vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In Vivo

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 609

Economic Impact of Adalimumab Treatment in Japanese Patients with Rheumatoid Arthritis from the Anouveau Study (Clinicaltrial.gov: NCT01346488)

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 421

Educating Patients on the Cardiovascular Risks of Rheumatoid Arthritis: Usual Care Versus a Structured Approach

Quality Measures and Quality of Care - Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].